| EPSRC Reference: |
EP/K503332/1 |
| Title: |
CENTRE FOR DOCTORAL TRAINING IN THE EPSRC CENTRE FOR INNOVATIVE MANUFACTURING IN EMERGENT MACROMOLECULAR THERAPIES |
| Principal Investigator: |
Dalby, Professor PA |
| Other Investigators: |
|
| Researcher Co-Investigators: |
|
| Project Partners: |
|
| Department: |
Biochemical Engineering |
| Organisation: |
UCL |
| Scheme: |
CDT - NR1 |
| Starts: |
01 October 2012 |
Ends: |
31 March 2019 |
Value (£): |
2,410,819
|
| EPSRC Research Topic Classifications: |
|
| EPSRC Industrial Sector Classifications: |
| Manufacturing |
Healthcare |
| Pharmaceuticals and Biotechnology |
|
|
| Related Grants: |
|
| Panel History: |
|
|
Summary on Grant Application Form |
The focus of the proposed EPSRC CDT will be on manufacturing research and training required in the most rapidly
developing parts of the UK bio-centred pharmaceutical and healthcare biotechnology sector, that have major implications
for future medicine. The bioprocess industry manufactures novel macromolecular drugs, proteins, to address a broad range
of chronic and debilitating human diseases. The UK holds a leading position by virtue of its science base and has unique university capabilities underpinning the sector. Whilst revenues are large, ~£110bn in 2009 on a worldwide basis, there are
huge pressures on the industry for change if demands for cost reduction and waste minimisation are to be met, and
populations are to benefit from the potent drugs becoming available. A sea change in manufacturing will be needed over
the next decade if the potential of modern drugs are to make their way through to widespread distribution. Moreover this is
a widely accepted skills shortage of individuals with the manufacturing research training needed for the sector.
Alignment to the EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies will deliver increased
national capability through training of the next generation of highly skilled and talented bioprocess manufacturing
researchers. Our aim is to train bioprocess engineering leaders of the future who will underpin translation of new scientific
advances into safely produced, more selective, therapies for currently intractable conditions at affordable costs. To achieve
this we will embed CDT PhDs within the vibrant research community of the top UK Institutions and that of the EPSRC
Centre for Innovative Manufacturing in Emergent Macromolecular Therapies, to ensure that they benefit in terms of impact
and knowledge transfer from the links to research led companies. The gearing in of these collaborations will enable the
CDT to explore new and emerging ideas in a training environment that draws on research excellence and to create strong
synergy between the Centre research programmes.
|
|
Key Findings |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Potential use in non-academic contexts |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Impacts |
|
| Description |
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk |
| Summary |
|
| Date Materialised |
|
|
|
|
Sectors submitted by the Researcher |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
| Project URL: |
|
| Further Information: |
|
| Organisation Website: |
|